Antipsychotic-Related Hypothermia: Five New Cases

Background: Hypothermia is a potentially fatal adverse effect of antipsychotic drug (APD) use. With only 69 cases described in the literature, the condition is considered rare.Methods: We describe five new cases, in which we estimated the role of clozapine, haloperidol, olanzapine, penfluridol, risp...

Full description

Bibliographic Details
Main Authors: Cherryl Zonnenberg, Jolien M. Bueno-de-Mesquita, Dharmindredew Ramlal, Jan Dirk Blom
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Psychiatry
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fpsyt.2019.00543/full
_version_ 1818135304339456000
author Cherryl Zonnenberg
Jolien M. Bueno-de-Mesquita
Dharmindredew Ramlal
Jan Dirk Blom
Jan Dirk Blom
Jan Dirk Blom
author_facet Cherryl Zonnenberg
Jolien M. Bueno-de-Mesquita
Dharmindredew Ramlal
Jan Dirk Blom
Jan Dirk Blom
Jan Dirk Blom
author_sort Cherryl Zonnenberg
collection DOAJ
description Background: Hypothermia is a potentially fatal adverse effect of antipsychotic drug (APD) use. With only 69 cases described in the literature, the condition is considered rare.Methods: We describe five new cases, in which we estimated the role of clozapine, haloperidol, olanzapine, penfluridol, risperidone, and zuclopentixol with the aid of two structured assessment tools.Results: In addition to APD use, all five patients described by us had been exposed to one or more additional predisposing factors for hypothermia. Therefore, with the aid of the assessment tools, the causal role of APDs was considered “possible” in four cases of moderate hypothermia and “doubtful” in the remaining one of mild hypothermia.Conclusion: Although the best way to detect APD-related hypothermia is measuring the body temperature for a duration of at least 7–10 days after the start (or a dose increase) of APDs, the use of assessment tools to identify additional predisposing factors for hypothermia and to thus establish their causal relationship with APD use would seem to be valuable for clinical decision-making (i.e., whether or not to discontinue APD use). Further research is needed to obtain reliable prevalence figures for APD-related hypothermia and its consequences, preferably in relation with physiological changes in body temperature.
first_indexed 2024-12-11T09:22:23Z
format Article
id doaj.art-388e5298332b4bcc8f70374aea98859b
institution Directory Open Access Journal
issn 1664-0640
language English
last_indexed 2024-12-11T09:22:23Z
publishDate 2019-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Psychiatry
spelling doaj.art-388e5298332b4bcc8f70374aea98859b2022-12-22T01:13:14ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402019-07-011010.3389/fpsyt.2019.00543455047Antipsychotic-Related Hypothermia: Five New CasesCherryl Zonnenberg0Jolien M. Bueno-de-Mesquita1Dharmindredew Ramlal2Jan Dirk Blom3Jan Dirk Blom4Jan Dirk Blom5Parnassia Academy, Parnassia Psychiatric Institute, The Hague, NetherlandsParnassia Academy, Parnassia Psychiatric Institute, The Hague, NetherlandsParnassia Academy, Parnassia Psychiatric Institute, The Hague, NetherlandsParnassia Academy, Parnassia Psychiatric Institute, The Hague, NetherlandsFaculty of Social Sciences, Leiden University, Leiden, NetherlandsDepartment of Psychiatry, University of Groningen, Groningen, NetherlandsBackground: Hypothermia is a potentially fatal adverse effect of antipsychotic drug (APD) use. With only 69 cases described in the literature, the condition is considered rare.Methods: We describe five new cases, in which we estimated the role of clozapine, haloperidol, olanzapine, penfluridol, risperidone, and zuclopentixol with the aid of two structured assessment tools.Results: In addition to APD use, all five patients described by us had been exposed to one or more additional predisposing factors for hypothermia. Therefore, with the aid of the assessment tools, the causal role of APDs was considered “possible” in four cases of moderate hypothermia and “doubtful” in the remaining one of mild hypothermia.Conclusion: Although the best way to detect APD-related hypothermia is measuring the body temperature for a duration of at least 7–10 days after the start (or a dose increase) of APDs, the use of assessment tools to identify additional predisposing factors for hypothermia and to thus establish their causal relationship with APD use would seem to be valuable for clinical decision-making (i.e., whether or not to discontinue APD use). Further research is needed to obtain reliable prevalence figures for APD-related hypothermia and its consequences, preferably in relation with physiological changes in body temperature.https://www.frontiersin.org/article/10.3389/fpsyt.2019.00543/fullbody temperatureneurolepticpharmacotherapypsychosisschizophreniaside effect
spellingShingle Cherryl Zonnenberg
Jolien M. Bueno-de-Mesquita
Dharmindredew Ramlal
Jan Dirk Blom
Jan Dirk Blom
Jan Dirk Blom
Antipsychotic-Related Hypothermia: Five New Cases
Frontiers in Psychiatry
body temperature
neuroleptic
pharmacotherapy
psychosis
schizophrenia
side effect
title Antipsychotic-Related Hypothermia: Five New Cases
title_full Antipsychotic-Related Hypothermia: Five New Cases
title_fullStr Antipsychotic-Related Hypothermia: Five New Cases
title_full_unstemmed Antipsychotic-Related Hypothermia: Five New Cases
title_short Antipsychotic-Related Hypothermia: Five New Cases
title_sort antipsychotic related hypothermia five new cases
topic body temperature
neuroleptic
pharmacotherapy
psychosis
schizophrenia
side effect
url https://www.frontiersin.org/article/10.3389/fpsyt.2019.00543/full
work_keys_str_mv AT cherrylzonnenberg antipsychoticrelatedhypothermiafivenewcases
AT jolienmbuenodemesquita antipsychoticrelatedhypothermiafivenewcases
AT dharmindredewramlal antipsychoticrelatedhypothermiafivenewcases
AT jandirkblom antipsychoticrelatedhypothermiafivenewcases
AT jandirkblom antipsychoticrelatedhypothermiafivenewcases
AT jandirkblom antipsychoticrelatedhypothermiafivenewcases